Dr. Paul Mathew Swanson, MD

Dr. Swanson practices at Hematology-Oncology Associates of the Treasure Coast in Port Saint Lucie, Florida.

Dr. Swanson's NPI, 1861448243, was assigned on May 26, 2006. Dr. Swanson graduated from Vanderbilt University School Of Medicine in 1992. Dr. Swanson holds Florida license 0075493.

Dr. Swanson's primary practice is Hematology-Oncology Associates of the Treasure Coast, at 1871 SE Tiffany Ave, Port Saint Lucie, FL 34952 in Saint Lucie County. The practice phone is (772) 335-5666.

Dr. Swanson's primary practice is Hematology-Oncology Associates of the Treasure Coast in Port Saint Lucie, Florida. Dr. Swanson is also affiliated with HCA Florida St. Lucie Hospital. The medical group on file is Hematology Oncology Associates of the Treasure Coast. Dmand AI also links Dr. Swanson to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Swanson practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Swanson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Swanson's licenses on file in 2 states: Florida and Tennessee.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Swanson treats.

CMS data shows 122,293 Medicare services from Dr. Swanson across 67 procedure codes in 2024, for 1,016 Medicare patients. Medicare paid $1,615,007 for them.

CMS counts 1,016 Medicare patients who saw Dr. Swanson in 2024. The largest group is 75 to 84, with 410 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Swanson's median patient age at 73, with 53% women.

In 2024, Dr. Swanson wrote 1,442 Medicare Part D claims for 279 patients. 71% of them were for generic drugs. CMS names the drug for 1,144 of them, across 38 drugs with 11 or more claims each, at $2,803,021 in total drug cost. In 2023, CMS named 1,491 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Swanson for performance year 2024, reported as part of a group. Dr. Swanson accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Swanson in 2017. Dr. Swanson's most frequent co-authors are David Eric Gerber, MD and Lucas Wong, MD.

Dmand AI links Dr. Swanson to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Swanson that name 2 trials.

CMS Open Payments shows 677 general payments to Dr. Swanson from 57 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,264. It also lists 4 research payments totaling $1,708 from 2018 to 2020, naming 2 clinical trials.

Dr. Swanson graduated from Vanderbilt University School Of Medicine in 1992. Dr. Swanson is a member of ACP.

Dr. Swanson is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.